Tempus AI, Inc. (TEM)
Tempus AI: Buy or Sell TEM Stock At $65?
Tempus AI stock has increased by 10% over the past week, fueled by impressive quarterly results and a raised sales forecast for the entire year. The company is now predicting an 82% year-over-year increase in sales, amounting to approximately $126 million.
Tempus AI, Inc. (TEM) Q2 2025 Earnings Call Transcript
Tempus AI, Inc. (NASDAQ:TEM ) Q2 2025 Earnings Conference Call August 8, 2025 8:00 PM ET Company Participants Elizabeth Krutoholow - Vice President of Investor Relations & Competitive Intelligence Eric P. Lefkofsky - Co-Founder, CEO, President & Chairman James Rogers - Chief Financial Officer Conference Call Participants Andrew Frederick Brackmann - William Blair & Company L.L.C.
Compared to Estimates, Tempus (TEM) Q2 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for Tempus (TEM) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
TEM's Q2 Earnings & Revenues Beat Estimates, Stock Up in Pre-Market
Tempus AI posts a narrower Q2 loss and an 89.6% revenue surge, driven by genomics growth and new oncology-focused product launches.
Tempus AI (TEM) Reports Q2 Loss, Beats Revenue Estimates
Tempus AI (TEM) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to a loss of $0.63 per share a year ago.
Tempus AI Targets Breast Cancer With Expanded Next - AI Platform
TEM expands its AI-driven Tempus Next platform into breast cancer, targeting key testing gaps to improve care delivery.
Tempus AI Stock Before Q2 Earnings Release: To Buy or Not to Buy?
TEM surged 34.5% in Q2 on AI-driven deals and product momentum, but valuation and profit concerns linger ahead of earnings.
Tempus AI: Data‑Driven Margin Lift, But Cash Burn Extends My Hold Stance
Tempus AI continues strong revenue growth, driven by its high-margin Data and Services segment and recent Ambry acquisition, but profitability remains elusive. Operational progress is evident, with expanding pharma partnerships and a growing AI-driven data platform, yet financial risks persist due to high cash burn and new debt. Upcoming Q2 results will be critical to assess sustainable profitability, margin stability, and growth in high-value contracts and test reimbursement rates.
Tempus AI: Sustaining Growth Momentum With Acquisitions & Partnerships
I am strongly bullish on Tempus AI due to its strategic partnerships, Ambry Genetics acquisition, and leadership in AI-driven precision oncology. Tempus' collaborations and acquisitions position it at the forefront of a rapidly growing oncology market, with an expected 80% revenue growth in 2025. Despite current net losses from high R&D, I project breakeven soon and a price target of $124 by 2029, a 91% upside.
Tempus AI (TEM) vs. Recursion (RXRX): Which AI Biotech Stock Is Better?
Tempus AI and Recursion Pharmaceuticals are fine ways to play the AI revolution from the health angle.
Tempus AI Gains FDA Nod Amid Booming AI ECG Market Momentum
TEM secures FDA clearance for its AI-powered ECG tool targeting heart failure, as AI ECG adoption accelerates.
TEM Shares Surge on New AI Breakthrough: Should Investors Jump In?
TEM stock rallies 7.3% after the FDA clears its second cardiology AI tool, witnessing a 48% surge in just three months.
